AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Ligand's 15min chart shows KDJ Golden Cross, Bullish Marubozu.
ByAinvest
Monday, Jul 7, 2025 1:33 pm ET1min read
Ligand's 15-minute chart recently exhibited a significant bullish technical indicator, as it triggered a KDJ Golden Cross and a Bullish Marubozu at 13:30 on July 7, 2025. This suggests a notable shift in momentum, with the stock price potentially continuing its upward trajectory. The strong presence of buyers in the market indicates a high likelihood of continued bullish momentum, underscoring the market's control by buyers.
Ligand Pharmaceuticals (LGND) has recently exhibited a notable bullish technical indicator, with its 15-minute chart triggering a KDJ Golden Cross and a Bullish Marubozu at 13:30 on July 7, 2025. This significant shift in momentum suggests a potential continuation of the stock's upward trajectory. The strong presence of buyers in the market indicates a high likelihood of sustained bullish momentum, underscoring the market's control by buyers.This positive technical signal comes amidst significant developments for Ligand, including the formation of Pelthos Therapeutics through a merger with Channel Therapeutics. Pelthos, which will begin trading under the ticker "PTHS" on NYSE American on July 2, 2025, secured $50.1 million in equity funding. Ligand itself invested $18 million and is set to receive a 13% royalty on the global sales of ZELSUVMI™, the first FDA-approved home-administered treatment for Molluscum contagiosum [1].
ZELSUVMI™ targets a market of 16.7 million potential patients in the US and is notable for being the first prescription medication that can be administered at home. The launch of ZELSUVMI is anticipated in July 2025, marking a significant move for Pelthos into the biopharmaceutical market.
Beyond the launch of ZELSUVMI, Pelthos plans to evaluate Channel's NaV 1.7 programs, which target various pain treatments, potentially expanding the company's avenue for future therapeutic solutions.
The bullish technical indicators and the strategic merger underscore the positive outlook for Ligand Pharmaceuticals, suggesting a strong potential for continued growth and investor interest.
References:
[1] https://www.gurufocus.com/news/2957060/ligand-announces-completion-of-pelthos-therapeutics-merger-with-channel-therapeutics-lgnd-stock-news
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet